Endpoint
Health-related quality of life
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease.
CAT:outcome/health-related-quality-of-lifereported in score4 findings from 3 compounds
What moved it
How to read these marks4 findings · 3 compounds · 2 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| magnesium(2+) | up | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| methylphenidate | up 1 · no effect 1 | 2 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| resveratrol | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Reported to move it
2 findings
magnesium(2+) — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“After adjusting for baseline serum magnesium and initial measurements, magnesium supplementation improved scores of role limitations due to emotional problems (p = 0.001), energy/fatigue (p = 0.010), emotional wellbeing (p < 0.001), general health (p = 0.042), and total quality of life (p < 0.001) compared with placebo.”
Quoted verbatim from The effects of magnesium supplementation on abnormal uterine bleeding, alopecia, quality of life, and acne in women with polycystic ovary syndrome: a randomized clinical trial.. - Study
- RCT
- Duration
- 2 months
- Dose
- 250 mg magnesium oxide tablet per day
- Population
- Women aged 18 to 45 with polycystic ovary syndrome, intention-to-treat; both arms received the same dietary recommendations; ANCOVA adjusted for baseline serum magnesium, energy intake and baseline values
The effects of magnesium supplementation on abnormal uterine bleeding, alopecia, quality of life, and acne in women with polycystic ovary syndrome: a randomized clinical trial.2022PMID:35918728Permalink
methylphenidate — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The change reported in a meta-analysis of three trials corresponds to a MD of 8.0 points (95% CI 5.49 to 10.46) on the CHQ, which suggests that methylphenidate may improve parent-reported quality of life (SMD 0.61, 95% CI 0.42 to 0.80; 3 trials, 514 participants; very low-quality evidence).”
Quoted verbatim from Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).. - Study
- meta-analysis
- Population
- Children and adolescents aged 18 years or younger with ADHD, parent-reported quality of life, meta-analysis of three trials against placebo or no intervention
Effect 0.61 standardised mean difference, 95% CI 0.42 to 0.8
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).2015PMID:26599576Permalink
Measured, no effect detected
2 findings
resveratrol — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“The administration of resveratrol did not affect cholesterol or triglyceride levels or the rates of depression, anxiety, sleep quality, or quality of life in PLHIV.”
Quoted verbatim from The Effects of Resveratrol in a Randomized Clinical Trial on Drug-Induced Hyperlipidemia and Psychiatric Factors in People Living with HIV.. - Study
- RCT
- Population
- people living with HIV (PLHIV)
The Effects of Resveratrol in a Randomized Clinical Trial on Drug-Induced Hyperlipidemia and Psychiatric Factors in People Living with HIV.2024PMID:39528454Permalink
methylphenidate — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Methylphenidate may improve teacher-rated general behaviour versus placebo (SMD -0.62, 95% CI -0.91 to -0.33; I² = 68%; 7 trials 792 participants; very low-certainty evidence), but may not affect quality of life (SMD 0.40, 95% CI -0.03 to 0.83; I² = 81%; 4 trials, 608 participants; very low-certainty evidence).”
Quoted verbatim from Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).. - Study
- meta-analysis
- Participants
- 608
- Population
- children and adolescents with ADHD; secondary outcome (quality of life), instrument not named by the review
Effect 0.4 standardised mean difference, 95% CI -0.03 to 0.83
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).2025PMID:41342306Permalink
How it is measured
Patient-reported health-related quality of life score on whichever validated multi-domain instrument the source administered (SF-36, EQ-5D, WHOQOL, or a disease-specific questionnaire), including estimates whose instrument the source did not name. The instrument, or the explicit fact that none was named, is recorded with each finding.
Measured, not recorded
- Subject
- health-related quality of life
- Measurements
- 3 measurements
- Recorded as a finding
- No
Show what was measured
health-related quality of life
increases
Health-related quality of life was higher in the LM group than in the systemic groups
PMID:32372561 · one of two readings recorded this
health-related quality of life
no effect, n = 592
One study assessed HRQoL, with no clinically meaningful decline compared to placebo/BSC (592 participants; moderate-certainty evidence)
PMID:40421698 · one of two readings recorded this
health-related quality of life
no effect, n = 399
showing no clear difference compared to chemotherapy, as assessed with the Functional Assessment of Cancer Therapy-Lung instrument (2 studies, 399 participants)
PMID:40421698 · one of two readings recorded this
Sources cited
4 papers
- Subject
- health-related quality of life
- Findings
- 4
- Papers
- 4
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).record2025PMID:413423061 finding
The Effects of Resveratrol in a Randomized Clinical Trial on Drug-Induced Hyperlipidemia and Psychiatric Factors in People Living with HIV.record2024PMID:395284541 finding
The effects of magnesium supplementation on abnormal uterine bleeding, alopecia, quality of life, and acne in women with polycystic ovary syndrome: a randomized clinical trial.record2022PMID:359187281 finding
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).record2015PMID:265995761 finding